No Data
No Data
Earnings Call: Bioventus Reports Robust Q3 Growth, Raises Full-year Guidance
Bioventus Is Maintained at Buy by Canaccord Genuity
Bioventus Analyst Ratings
Craig-Hallum Maintains Bioventus(BVS.US) With Buy Rating, Announces Target Price $17
CCORF Maintains Bioventus(BVS.US) With Buy Rating, Raises Target Price to $15
J.P. Morgan Maintains Bioventus(BVS.US) With Sell Rating, Announces Target Price $12
No Data
No Data